A Phase 3 interventional study of Pacritinib and Best Available Therapy in Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, sponsored by CTI BioPharma. Terminated at 81 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-29.
Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.
Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 3rd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas · Sites in Spain
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 327 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 35 across the 18 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under CTI BioPharma, one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Swedish Orphan Biovitrum has 7 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
2 of the studies testing pacritinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing pacritinib in Primary Myelofibrosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
Multicenter, randomized, controlled, phase 3 trial comparing the safety and efficacy of pacritinib with that of BAT in patients with primary or secondary myelofibrosis. Approximately 322 eligible patients will be randomized in a 2:1 allocation to pacritinib (400mg QD) or BAT (includes any physician-selected treatment for myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)). Spleen volume will be measured by MRI or CT at baseline and every 12 weeks thereafter. An independent radiology facility (IRF), blind to treatment assignments, will measure spleen volumes. Patients will also be followed for safety, Leukemia Free Survival (LFS), Overall Survival (OS), frequency of red blood cell (RBC) and platelet transfusions, and other exploratory endpoints. An Independent Data Monitoring Committee (IDMC) will evaluate the safety of pacritinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pacritinib 400 mg QD
Drug: Pacritinib
BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
Drug: Best Available Therapy
Spleen Volume Reduction
Number of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)
Time frame: Baseline to Week 24
Total Symptom Score (TSS) Reduction
Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.
Time frame: Baseline to Week 24
| Milestone | Pacritinib | Best Available Therapy |
|---|---|---|
| Started | 220 | 107 |
| Completed | 167 | 75 |
| Not completed | 53 | 32 |
Number of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)
| Participants | Pacritinib | Best Available Therapy |
|---|---|---|
| Spleen Volume Reduction | 42 | 5 |
Number of patients with \>= 50% reduction in total score from baseline to week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.
| Participants | Pacritinib | Best Available Therapy |
|---|---|---|
| Total Symptom Score (TSS) Reduction | 19 | 5 |
Collected over Time of signing informed consent through 30 days after the last study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pacritinib | 27/220 (12.3%) | 117/220 (53.2%) | 207/220 (94.1%) |
| Best Available Therapy | 3/106 (2.8%) | 33/106 (31.1%) | 81/106 (76.4%) |
| Event | Pacritinib | Best Available Therapy |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 16/220 | 5/106 |
| PneumoniaInfections and infestations | 16/220 | 4/106 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/220 | 4/106 |
| Cardiac FailureCardiac disorders | 7/220 | 3/106 |
| Disease ProgressionGeneral disorders | 6/220 | 3/106 |
| PyrexiaGeneral disorders | 6/220 | 3/106 |
| Basal cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/220 | 2/106 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/220 | 0/106 |
| DiarrhoeaGastrointestinal disorders | 4/220 | 2/106 |
| SepisInfections and infestations | 2/220 | 2/106 |
| Event | Pacritinib | Best Available Therapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 142/220 | 14/106 |
| NauseaGastrointestinal disorders | 70/220 | 7/106 |
| AnaemiaBlood and lymphatic system disorders | 58/220 | 18/106 |
| ThrombocytopeniaBlood and lymphatic system disorders | 48/220 | 15/106 |
| VomitingGastrointestinal disorders | 46/220 | 7/106 |
| Oedema peripheralGeneral disorders | 24/220 | 16/106 |
| FatigueGeneral disorders | 33/220 | 9/106 |
| Abdominal painGastrointestinal disorders | 29/220 | 11/106 |
| PyrexiaGeneral disorders | 17/220 | 11/106 |
| ConstipationGastrointestinal disorders | 22/220 | 8/106 |
Represents Intent To Treat population (number of randomized patients)
| Age, Categorical(Participants) | Pacritinib | Best Available Therapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 85 | 52 | 137 |
| >=65 years | 135 | 55 | 190 |
| Age, Continuous(years) | Pacritinib | Best Available Therapy | Total |
|---|---|---|---|
| Mean | 65.5 ± 10.85 | 64.8 ± 9.12 | 65.3 ± 10.31 |
| Sex: Female, Male(Participants) | Pacritinib | Best Available Therapy | Total |
|---|---|---|---|
| Female | 95 | 47 | 142 |
| Male | 125 | 60 | 185 |
| Region of Enrollment(participants) | Pacritinib | Best Available Therapy | Total |
|---|---|---|---|
| New Zealand | 16 | 4 | 20 |
| Netherlands | 13 | 8 | 21 |
| Belgium | 8 | 1 | 9 |
| Hungary | 49 | 21 | 70 |
| Czechia | 9 | 9 | 18 |
| United States | 3 | 2 | 5 |
| Italy | 11 | 10 | 21 |
| United Kingdom | 19 | 6 | 25 |
| Australia | 29 | 17 | 46 |
| France | 26 | 9 | 35 |
| Germany | 2 | 2 | 4 |
| Russia | 35 | 18 | 53 |
Ran from Jan 2013 to primary completion in Jan 2015, 24 months.
Results were first posted in Sep 2020, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pacritinib